Measurement invariance of the Schizotypal Personality Questionnaire-Brief across gender and age

  1. Fonseca-Pedrero, E. 12
  2. Paino, M. 12
  3. Lemos-Giráldez, S. 12
  4. Sierra-Baigrie, S. 12
  5. Muñiz, J. 12
  1. 1 Centro de Investigacion Biomedica en Red de Salud Mental
    info

    Centro de Investigacion Biomedica en Red de Salud Mental

    Madrid, España

    ROR https://ror.org/009byq155

  2. 2 Universidad de Oviedo
    info

    Universidad de Oviedo

    Oviedo, España

    ROR https://ror.org/006gksa02

Journal:
Psychiatry Research

ISSN: 0165-1781

Year of publication: 2011

Volume: 190

Issue: 2-3

Pages: 309-315

Type: Article

DOI: 10.1016/J.PSYCHRES.2011.05.021 PMID: 21663975 SCOPUS: 2-s2.0-82955237221 GOOGLE SCHOLAR

More publications in: Psychiatry Research

Abstract

The purpose of this study was to examine the dimensional structure and measurement invariance of the Schizotypal Personality Questionnaire-Brief (SPQ-B) (Raine and Benishay, 1995) across sex and age in a representative sample of nonclinical adolescents and young adults. The sample consisted of 1789 adolescents and young adults (42.1% males), with a mean age of 17.1. years (S.D.= 2.9). The results indicated that the Likert version of the SPQ-B showed adequate psychometric properties (α total score 0.89). The schizotypal personality models that presented the best fit indices were Raine et al.'s (1994) three-factor model and Stefanis et al.'s (2004) four-factor model. In addition, the results support the measurement invariance of the SPQ-B across sex and age. When the latent means of the schizotypal dimensions were compared across sex and age, statistically significant differences were found. Consistent with previous literature, schizotypal personality is a multidimensional construct whose structure appears invariant across sex and age. Future studies should examine the invariance of schizotypal personality across cultures, as well as using the SPQ-B as a screening method in the general population to detect individuals at risk for schizophrenia-spectrum disorders, given its rapid and easy administration. © 2011 Elsevier Ltd.